[Infection by BK virus, a human papovavirus, in immunosuppressed children and in children with normal immunological defenses (author's transl)]. 1981

M Baserga, and M Borgatti, and A Nicoli, and M Portolani, and P Rosito, and G Paolucci

Human infection by BK virus (BKV), a human papovavirus isolated from the urine of a transplanted patient, occurs early in life and is very widespread. The clinical features of the primary infection are unknown. After the primary infection, BKV remains latent in the host tissues. Immunosuppression of the host induces the activation of the latent virus; BKV has been isolated only from immunosuppressed patients so far. In our study the incidence of BKV infection in immunosuppressed children and in children with normal immunological defenses was investigated both by antibody and virus research, the cultural research of the virus being performed in the urine and other specimens, such as nasal-pharyngeal swabs and cerebrospinal fluids. Our results show that the incidence of the primary infection in immunosuppressed children is comparable to the incidence in children with normal immunological defenses. Two antigenically identical viruses, which showed only partial correlation with BKV, were isolated from the urine of two immunosuppressed children. These two viruses were considered as a same antigenic variant of the BKV prototype. Of all the subjects examined, only 9 immunosuppressed children had antibodies to the newly isolated viruses.

UI MeSH Term Description Entries
D007165 Immunosuppression Therapy Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs. Antirejection Therapy,Immunosuppression,Immunosuppressive Therapy,Anti-Rejection Therapy,Therapy, Anti-Rejection,Therapy, Antirejection,Anti Rejection Therapy,Anti-Rejection Therapies,Antirejection Therapies,Immunosuppression Therapies,Immunosuppressions,Immunosuppressive Therapies,Therapies, Immunosuppression,Therapies, Immunosuppressive,Therapy, Immunosuppression,Therapy, Immunosuppressive
D007223 Infant A child between 1 and 23 months of age. Infants
D011120 Polyomavirus A genus of potentially oncogenic viruses of the family POLYOMAVIRIDAE. These viruses are normally present in their natural hosts as latent infections. The virus is oncogenic in hosts different from the species of origin. Bovine polyomavirus,Murine polyomavirus,Hamster polyomavirus,Polyoma Virus,Polyoma Viruses,Bovine polyomaviruses,Hamster polyomaviruses,Murine polyomaviruses,Polyomaviruses,Virus, Polyoma,Viruses, Polyoma,polyomavirus, Hamster,polyomaviruses, Bovine,polyomaviruses, Murine
D001739 BK Virus A species of POLYOMAVIRUS apparently infecting over 90% of children but not clearly associated with any clinical illness in childhood. The virus remains latent in the body throughout life and can be reactivated under certain circumstances. BK polyomavirus,Human Polyomavirus BK,Polyomavirus, BK,Polyomavirus hominis 1,Polyomavirus BK, Human
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000914 Antibodies, Viral Immunoglobulins produced in response to VIRAL ANTIGENS. Viral Antibodies

Related Publications

M Baserga, and M Borgatti, and A Nicoli, and M Portolani, and P Rosito, and G Paolucci
October 1976, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
M Baserga, and M Borgatti, and A Nicoli, and M Portolani, and P Rosito, and G Paolucci
April 1975, Journal of the National Cancer Institute,
M Baserga, and M Borgatti, and A Nicoli, and M Portolani, and P Rosito, and G Paolucci
June 1977, Laboratory investigation; a journal of technical methods and pathology,
M Baserga, and M Borgatti, and A Nicoli, and M Portolani, and P Rosito, and G Paolucci
November 1973, Proceedings of the National Academy of Sciences of the United States of America,
M Baserga, and M Borgatti, and A Nicoli, and M Portolani, and P Rosito, and G Paolucci
November 1977, Journal of the National Cancer Institute,
M Baserga, and M Borgatti, and A Nicoli, and M Portolani, and P Rosito, and G Paolucci
March 1976, Journal of virology,
M Baserga, and M Borgatti, and A Nicoli, and M Portolani, and P Rosito, and G Paolucci
November 1974, Journal of medical microbiology,
M Baserga, and M Borgatti, and A Nicoli, and M Portolani, and P Rosito, and G Paolucci
January 1980, Microbiology and immunology,
M Baserga, and M Borgatti, and A Nicoli, and M Portolani, and P Rosito, and G Paolucci
January 1981, Journal of medical virology,
M Baserga, and M Borgatti, and A Nicoli, and M Portolani, and P Rosito, and G Paolucci
September 1978, Journal of the National Cancer Institute,
Copied contents to your clipboard!